Wilson W. Bryan
University of Texas Southwestern Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Wilson W. Bryan.
Muscle & Nerve | 1999
David Saperstein; Anthony A. Amato; Gil I. Wolfe; Jonathan S. Katz; Sharon P. Nations; Carlayne E. Jackson; Wilson W. Bryan; Dennis K. Burns; Richard J. Barohn
We report 11 patients with multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy, defined clinically by a multifocal pattern of motor and sensory loss, with nerve conduction studies showing conduction block and other features of demyelination. The clinical, laboratory, and histological features of these patients were contrasted with those of 16 patients with multifocal motor neuropathy (MMN). Eighty‐two percent of MADSAM neuropathy patients had elevated protein concentrations in the cerebrospinal fluid, compared with 9% of the MMN patients (P < 0.001). No MADSAM neuropathy patient had elevated anti‐GM1 antibody titers, compared with 56% of MMN patients (P < 0.01). In contrast to the subtle abnormalities described for MMN, MADSAM neuropathy patients had prominent demyelination on sensory nerve biopsies. Response to intravenous immunoglobulin treatment was similar in both groups (P = 1.0). Multifocal motor neuropathy patients typically do not respond to prednisone, but 3 of 6 MADSAM neuropathy patients improved with prednisone. MADSAM neuropathy more closely resembles chronic inflammatory demyelinating polyneuropathy and probably represents an asymmetrical variant. Given their different clinical patterns and responses to treatment, it is important to distinguish between MADSAM neuropathy and MMN.
Neurology | 2001
Robert G. Miller; Dan H. Moore; Deborah F. Gelinas; V. Dronsky; Michelle Mendoza; Richard J. Barohn; Wilson W. Bryan; John Ravits; E. Yuen; Hans E. Neville; Steven P. Ringel; Mark B. Bromberg; Jack H. Petajan; Anthony A. Amato; Carlayne E. Jackson; W. Johnson; Raul N. Mandler; P. Bosch; Benn E. Smith; Michael C. Graves; Mark A. Ross; Eric J. Sorenson; Praful Kelkar; Gareth Parry; Richard K. Olney
Background: Preclinical and clinical studies of gabapentin in patients with ALS led the authors to undertake a phase III randomized clinical trial. Methods: Patients were randomly assigned, in a double-blinded fashion, to receive oral gabapentin 3,600 mg or placebo daily for 9 months. The primary outcome measure was the average rate of decline in isometric arm muscle strength for those with two or more evaluations. Results: Two hundred four patients enrolled, 196 had two or more evaluations, and 128 patients completed the study. The mean rate of decline of the arm muscle strength was not significantly different between the groups. Moreover, there was no beneficial effect upon the rate of decline of other secondary measures (vital capacity, survival, ALS functional rating scale, timed walking) nor was there any symptomatic benefit. In fact, analysis of the combined data from the phase II and III trials revealed a significantly more rapid decline of forced vital capacity in patients treated with gabapentin. Conclusion: These data provide no evidence of a beneficial effect of gabapentin on disease progression or symptoms in patients with ALS.
Neurology | 1999
Gil I. Wolfe; Laura Herbelin; Sharon P. Nations; Barbara Foster; Wilson W. Bryan; Richard J. Barohn
Article abstract The authors have developed an MG activities of daily living (ADL) profile (MG-ADL)—a simple eight-question survey of MG symptoms. In 254 consecutive encounters with established MG patients, the authors compared scores from the MG-ADL to the quantitative MG score (QMG)—a standardized, reliable scale used in clinical trials. The mean MG-ADL score was 4.89 ± 3.63. The mean QMG score was 10.80 ± 5.70. Pearson’s correlation coefficient was 0.583 (p < 0.001). The MG-ADL is an easy-to-administer survey of MG that correlates well with the QMG and can serve as a secondary efficacy measurement in clinical trials.
Neurology | 1997
Jonathan S. Katz; Gil I. Wolfe; Wilson W. Bryan; Carlayne E. Jackson; Anthony A. Amato; Richard J. Barohn
Article abstract-We performed detailed electrophysiologic studies on 16 patients with clinically defined multifocal motor neuropathy and found a wide spectrum of demyelinating features. Only five patients (31%) had conduction block in one or more nerves. However, in 15 patients (94%) at least one nerve showed other features of demyelination. We also noted a significant degree of superimposed axonal degeneration in 15 patients. Eight patients (50%) had individual nerves with pure axonal injury, despite the presence of demyelinating features in other nerves. Antiganglioside antibodies were elevated in four of five patients with conduction block and five of 11 patients without conduction block. We conclude that multifocal motor neuropathy is characterized electrophysiologically by a wide spectrum of axonal and demyelinating features. Diagnostic criteria requiring conduction block may lead to underdiagnosis of this potentially treatable neuropathy. NEUROLOGY 1997;48: 700-707
Neurology | 1996
Robert G. Miller; Wilson W. Bryan; M.A. Dietz; T.L. Munsat; Jack H. Petajan; Stephen Smith; Jessie C. Goodpasture
We examined the toxicity of both single and multiple subcutaneous injections of recombinant human ciliary neurotrophic factor (rhCNTF) in 72 patients with ALS, in doses ranging from 2 to 100 micro gram/kg.Adverse events were generally dose related and ranged from mild to severe. The tolerability of daily subcutaneous rhCNTF was equivalent to placebo at doses <or=to 5 micro gram/kg/day. At higher doses, anorexia, weight loss, reactivation of herpes simplex virus (HSV1) labialis/stomatitis, cough, and increased oral secretions occurred. NEUROLOGY 1996;47: 1329-1331
Neurology | 1998
Mark A. Ross; Robert G. Miller; L. Berchert; Gareth Parry; Richard J. Barohn; Carmel Armon; Wilson W. Bryan; Jack H. Petajan; Scott C. Stromatt; Jessie C. Goodpasture; Dawn McGuire
We modified the World Federation of Neurology (WFN) diagnostic criteria for ALS to facilitate early diagnosis and used these criteria for enrollment of ALS patients in a clinical trial. The criteria developed required lower motor neuron (LMN) involvement in at least two limbs and upper motor neuron involvement in at least one region (bulbar, cervical, or lumbosacral). The EMG finding of fibrillation potentials was required for evidence of LMN involvement. Electrodiagnostic studies, neuroimaging, and laboratory studies were also used to exclude disorders that might mimic ALS. Using these criteria, the diagnosis of ALS was made at a mean time of 9.7 months from onset of symptoms, which compares favorably with the 12-month period cited in the literature. Using clinical assessment at completion of the trial, the diagnosis of ALS was believed to be accurate in those patients entered in the trial. However, pathologic confirmation of the diagnosis of ALS was not obtained. Based on our preliminary experience, we propose that these ALS diagnostic criteria will facilitate early diagnosis of ALS. Future studies should prospectively compare these criteria with the WFN criteria currently in use.
Muscle & Nerve | 2002
Gil I. Wolfe; Richard J. Barohn; Barbara Foster; Carlayne E. Jackson; John T. Kissel; John W. Day; Charles A. Thornton; Sharon P. Nations; Wilson W. Bryan; Anthony A. Amato; Miriam Freimer; Gareth Parry
We initiated a randomized, double‐blinded, placebo‐controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6‐week open‐label study of IVIG, positive trends were observed.
Magnetic Resonance Imaging | 1993
Alan Pitt; James L. Fleckenstein; Ralph G. Greenlee; Dennis K. Burns; Wilson W. Bryan; Ronald G. Haller
The purpose of this report is to describe our initial experience with techniques employing magnetic resonance imaging (MRI) to guide the choice of muscle to be biopsied in patients suspected of having inflammatory myopathy. Five patients with a clinical diagnosis of inflammatory myopathy (IM) were studied. Four were imaged prior to biopsy. Four had repeated examinations, either immediately following biopsy or to evaluate disease progression. Use of MRI to localize muscle lesions was associated with abnormal pathologic findings in all cases, including histopathologic demonstration of lymphocyte infiltration in three cases of idiopathic polymyositis; nonspecific myopathic changes were seen in one patient with probable dermatomyositis and in one patient with chronic inflammatory polyneuropathy and high serum creatine kinase levels (> 45,000 IU/ml). The precise location of the area sampled by biopsy was visible in only one of four postbiopsy images. MRI shows promise in identifying pathologic muscle in patients suspected of having one of the inflammatory myopathies; however, further refinement of localization techniques may be needed to optimize histopathologic diagnoses.
Muscle & Nerve | 1996
Anthony A. Amato; Gary S. Gronseth; Kevin J. Callerame; Kathleen S. Kagan-Hallet; Wilson W. Bryan; Richard J. Barohn
Tomaculous neuropathy is the descriptive term for the “sausagelike” swellings of myelin characteristic of hereditary neuropathy with liability to pressure palsies (HNPP). A 1.5‐Mb deletion in chromosome 17p11.2 is present in the majority but not all cases of HNPP. We reviewed the clinical and electrophysiological features of 18 patients with tomaculous neuropathy and compared these features between patients with and without the typical large deletion. Patients presented with a variety of pressure‐induced nerve palsies and brachial plexopathies. Two patients presented with generalized symmetric sensorimotor polyneuropathies. Four patients were older than their respective probands but were as yet asymptomatic. Nerve conduction studies demonstrated prolonged distal latencies out of proportion to slowing of conduction velocities, suggesting a distally accentuated myelinopathy. DNA analysis revealed the 1.5‐Mb deletion in all the familial cases and in 3 of the sporadic patients. The clinical and electrophysiological features were similar between patients with and without the 1.5‐Mb deletion in chromosome 17p11.2.
Neurology | 1999
Sharon P. Nations; Gil I. Wolfe; Anthony A. Amato; Carlayne E. Jackson; Wilson W. Bryan; Richard J. Barohn
Article abstract Myasthenia gravis (MG) characteristically involves ocular, bulbar, and proximal extremity muscles. Distal extremity muscles are typically spared or less prominently involved. The authors performed a retrospective chart review of MG patients treated at two university-based neuromuscular clinics. From a total population of 236, nine patients (3%) had distal extremity weakness exceeding proximal weakness by at least one Medical Research Council grade during their illness. Hand muscles, particularly finger extensors, were involved more frequently than were distal leg and foot muscles.
Collaboration
Dive into the Wilson W. Bryan's collaboration.
University of Texas Health Science Center at San Antonio
View shared research outputs